A phase 2 trial of nab-paclitaxel, oxaliplatin, S1 and itraconazole for unresectable pancreatic cancer

A phase 2 trial of nab-paclitaxel, oxaliplatin, S1 and itraconazole for unresectable pancreatic cancer - Combination chemotherapy with itraconazole for pancreatic cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025398

Enrollment

Registered

2016-12-27

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable pancreatic cancer

Interventions

itraconazole 400 mg po day -2~+3 nabpaclitaxel 125 mg/m2 day 1 gemcitabine 1000 mgm2 day 1 L-OHP 85 mg/m2 day 1 q14d

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Stage IV pancreatic cancer no previous chemotherapy

Exclusion criteria

Exclusion criteria: diarrhea

Design outcomes

Primary

Measure	Time frame
Response rate, operability	—

Secondary

Measure	Time frame
Overall survival, progression free survival, disease conctrol rate, adverse events	—

Countries

Japan

Contacts

Public ContactTakashi Sonoda

Meiwa Hospital Medical Oncology

tsuba@hyo-med.ac.jp0798-47-1767

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026